Fulcrum Therapeutics Stock Performance
| FULC Stock | USD 7.28 0.16 2.15% |
Fulcrum Therapeutics has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 2.56, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Fulcrum Therapeutics will likely underperform. Fulcrum Therapeutics right now shows a risk of 3.98%. Please confirm Fulcrum Therapeutics jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to decide if Fulcrum Therapeutics will be following its price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Fulcrum Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain essential indicators, Fulcrum Therapeutics may actually be approaching a critical reversion point that can send shares even higher in May 2024. ...more
Actual Historical Performance (%)
One Day Return (1.75) | Five Day Return 4.43 | Year To Date Return 1.39 | Ten Year Return (45.85) | All Time Return (45.85) |
1 | Acquisition by Tourangeau Greg of 83820 shares of Fulcrum Therapeutics subject to Rule 16b-3 | 01/30/2024 |
2 | Fulcrum Therapeutics files for 350M mixed shelf | 02/27/2024 |
3 | Acquisition by Sapir Alex of 43360 shares of Fulcrum Therapeutics at 11.3475 subject to Rule 16b-3 | 03/04/2024 |
4 | Fulcrum stock jumps as CEO buys shares | 03/06/2024 |
5 | Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 03/08/2024 |
6 | Fulcrum Therapeutics, Inc. Receives Average Recommendation of Moderate Buy from Analysts - MarketBeat | 03/15/2024 |
7 | Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer | 03/18/2024 |
8 | Is Fulcrum Therapeutics Inc Stock a Bad Value Tuesday - InvestorsObserver | 03/26/2024 |
9 | Fulcrum Therapeutics, Inc. Receives Average Rating of Moderate Buy from Brokerages - Defense World | 04/09/2024 |
10 | Short Interest in Fulcrum Therapeutics, Inc. Drops By 5.4 percent - MarketBeat | 04/16/2024 |
| Begin Period Cash Flow | 35.1 M | |
| Free Cash Flow | -91.5 M |
Fulcrum |
Fulcrum Therapeutics Relative Risk vs. Return Landscape
If you would invest 700.00 in Fulcrum Therapeutics on January 25, 2024 and sell it today you would earn a total of 28.00 from holding Fulcrum Therapeutics or generate 4.0% return on investment over 90 days. Fulcrum Therapeutics is currently generating 0.1395% in daily expected returns and assumes 3.9814% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Fulcrum, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Fulcrum Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fulcrum Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Fulcrum Therapeutics, and traders can use it to determine the average amount a Fulcrum Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.035
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | FULC | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.98 actual daily | 35 65% of assets are more volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 2 98% of assets perform better |
Based on monthly moving average Fulcrum Therapeutics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fulcrum Therapeutics by adding it to a well-diversified portfolio.
Fulcrum Therapeutics Fundamentals Growth
Fulcrum Stock prices reflect investors' perceptions of the future prospects and financial health of Fulcrum Therapeutics, and Fulcrum Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fulcrum Stock performance.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (32.14) % | ||||
| Current Valuation | 235.4 M | ||||
| Shares Outstanding | 62.15 M | ||||
| Price To Earning | (1.99) X | ||||
| Price To Book | 1.98 X | ||||
| Price To Sales | 165.60 X | ||||
| Revenue | 2.81 M | ||||
| Gross Profit | (70.44 M) | ||||
| EBITDA | (108.49 M) | ||||
| Net Income | (97.33 M) | ||||
| Cash And Equivalents | 221.79 M | ||||
| Cash Per Share | 4.26 X | ||||
| Total Debt | 10.82 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 15.49 X | ||||
| Book Value Per Share | 3.80 X | ||||
| Cash Flow From Operations | (90.97 M) | ||||
| Earnings Per Share | (1.59) X | ||||
| Market Capitalization | 462.42 M | ||||
| Total Asset | 257.69 M | ||||
| Retained Earnings | (509.67 M) | ||||
| Working Capital | 228.52 M | ||||
| Current Asset | 22.54 M | ||||
| Current Liabilities | 3.5 M | ||||
About Fulcrum Therapeutics Performance
To evaluate Fulcrum Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Fulcrum Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Fulcrum Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Fulcrum Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Fulcrum's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (148.15) | (140.74) | |
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.45) | (0.48) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (0.41) | (0.43) |
Things to note about Fulcrum Therapeutics performance evaluation
Checking the ongoing alerts about Fulcrum Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fulcrum Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fulcrum Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 2.81 M. Net Loss for the year was (97.33 M) with loss before overhead, payroll, taxes, and interest of (70.44 M). | |
| Fulcrum Therapeutics currently holds about 221.79 M in cash with (90.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26. | |
| Fulcrum Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Short Interest in Fulcrum Therapeutics, Inc. Drops By 5.4 percent - MarketBeat |
- Analyzing Fulcrum Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fulcrum Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Fulcrum Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fulcrum Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fulcrum Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fulcrum Therapeutics' stock. These opinions can provide insight into Fulcrum Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Fulcrum Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.272 | Return On Assets (0.29) | Return On Equity (0.45) |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.